The optimal conversion ratio of tacrolimus switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving posaconazole prophylaxis with and without letermovir.

tacrolimus intravenous - Generic mfg.

Prevymis (letermovir) - Merck (MSD)

Noxafil (posaconazole) - Merck (MSD)

tacrolimus oral - Generic mfg.

The optimal conversion ratio of tacrolimus switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving posaconazole prophylaxis with and without letermovir. (PubMed, Jpn J Clin Oncol) - Jun 10, 2025 - "The median (C/Dpo)/(C/Dciv) ratios were 0.25 and 0.24, respectively (P = 0.77), indicating no significant difference in tacrolimus conversion ratios with and without letermovir. Based on these findings, the tacrolimus conversion ratio in patients receiving posaconazole was estimated to be approximately 1:2, regardless of concomitant letermovir use."
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Transplantation • CYP2C19 • CYP2C9 • CYP3A4

http://www.ncbi.nlm.nih.gov/pubmed/40493965

Ayumu Ito; Azusa Kawasaki; Hironobu Hashimoto; Takahiro Fukuda; Toshihisa Nakashima; Yoshihiro Inamoto

Jun 10, 2025